Reported results
- GAAP revenues for the three months ended September 30, 2026, were $55,463, compared to $15,606 for the same period in 2025.
- GAAP research and development expenses for the three months ended September 30, 2026, were $1,242,577, compared to $1,404,247 for the same period in 2025.
- GAAP general and administrative expenses for the three months ended September 30, 2026, were $1,366,386, compared to $1,884,994 for the same period in 2025.
- GAAP net loss for the three months ended September 30, 2026, was $3,222,829, compared to $4,554,336 for the same period in 2025.
- The Company raised $8.6 million of equity financing in the nine months ended September 30, 2026.
- The Company secured up to $10.0 million in cash through debt financing on November 4, 2026.
Guidance
- Phase 1 readout and determination of the Recommended Phase 2 Dose for HCW9302 are expected in the first quarter of 2027.
- The Company intends to file an IND application to support a first-in-human clinical study to evaluate HCW11-018b in the first half of 2027.
Notes
As of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
